+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Hormonal Contraceptive Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797862
The global hormonal contraceptive market value was USD 16.8 billion in 2022, driven by the increasing awareness regarding family planning across the globe. The market size is anticipated to grow at a CAGR of 4.1% during the forecast period of 2023-2031 to achieve a value of USD 24.1 billion by 2031.

Hormonal Contraceptive: Introduction

Hormonal contraceptives work by preventing ovulation or thickening cervical mucus to block sperm from reaching an egg. Some of the different types of hormonal contraceptives include the birth control pill, hormonal intrauterine devices (IUDs), the contraceptive patch, and the contraceptive injection.

The development of hormonal contraceptives has been a significant advancement in the field of reproductive health, giving women greater control over their reproductive choices. Companies in this market aim to create safe and effective birth control options with minimal side effects.

The hormonal contraceptive market is highly competitive, with many companies vying to create the next breakthrough contraceptive. In recent years, there has been a growing demand for long-acting reversible contraceptives (LARCs) such as hormonal IUDs and contraceptive implants. Additionally, there is a trend towards developing contraceptives with fewer or no side effects, as well as non-hormonal contraceptive options.

Hormonal Contraceptive Market Scenario

The market for hormonal contraceptive is a rapidly growing market. The increasing awareness regarding family planning and the need for safe and effective contraceptives are the major driving factors for the growth of this market. The use of hormonal contraceptive methods has increased in recent years due to the ease of use, reliability, and effectiveness of these methods. The market is also driven by the rise in population and the need to control it. Additionally, the increasing incidence of sexually transmitted diseases (STDs) is driving the growth of the market as hormonal contraceptives are effective in reducing the risk of STDs.

However, the market is facing challenges such as the side effects associated with the use of hormonal contraceptives, which has led to a decline in their adoption rate. The high cost of these contraceptives is also a restraining factor for market growth.

Hormonal Contraceptive Market Segmentations

Market Breakup by Method

  • Pills
  • Intrauterine Devices (IUD)
  • Injectables
  • Vaginal Ring
  • Implant
  • Patch

Market Breakup by Hormonals

  • Androgens
  • Estrogens
  • Progesterone
  • Antiandrogens
  • Gonadotrophins
  • Others

Market Breakup by Gender

  • Male
  • Female

Market Breakup by End User

  • Hospitals
  • Homecare
  • Clinics
  • Gynecology Centers
  • Ambulatory Surgical Centers (ASC)

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Hormonal Contraceptive Market

Some key trends in the hormonal contraceptive market are:
  • Increasing popularity of long-acting reversible contraception (LARC) methods such as hormonal intrauterine devices (IUDs) and contraceptive implants
  • Growing demand for personalized and effective hormonal contraceptive options for women
  • Technological advancements in the development of hormonal contraceptives, such as the use of progestin-only pills and non-oral methods of delivery such as patches, injections, and vaginal rings
  • Rising awareness about the importance of family planning and the benefits of using hormonal contraceptives
  • Increasing focus on developing affordable and accessible hormonal contraceptives for women in developing countries
  • Growing adoption of digital health technologies and telemedicine for the distribution of hormonal contraceptives and related services
  • Emergence of new players and partnerships in the market, leading to increased competition and innovation in the industry

Hormonal Contraceptive Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Allergan Inc
  • Pfizer Inc
  • Bayer AG
  • Afaxys, Inc
  • Merck and Co., Inc
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Reckitt Benckiser Group plc
  • Boehringer Ingelheim International GmbH
  • Agile Technologies
  • Warner Chilcott
  • Novartis AG

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Hormonal Contraceptive Market Overview
3.1 Global Hormonal Contraceptive Market Historical Value (2016-2022)
3.2 Global Hormonal Contraceptive Market Forecast Value (2023-2031)
4 Global Hormonal Contraceptive Market Landscape
4.1 Global Hormonal Contraceptive Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Hormonal Contraceptive Product Landscape
4.2.1 Analysis by Method
4.2.2 Analysis by Hormonals
4.2.3 Analysis by Gender
4.2.4 Analysis by End User
5 Global Hormonal Contraceptive Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Hormonal Contraceptive Market Segmentation
6.1 Global Hormonal Contraceptive Market by Method
6.1.1 Market Overview
6.1.2 Pills
6.1.3 Intrauterine Devices (IUD)
6.1.4 Injectables
6.1.5 Vaginal Ring
6.1.6 Implant
6.1.7 Patch
6.2 Global Hormonal Contraceptive Market by Hormonals
6.2.1 Market Overview
6.2.2 Androgens
6.2.3 Estrogens
6.2.4 Progesterone
6.2.5 Antiandrogens
6.2.6 Gonadotrophins
6.2.7 Others
6.3 Global Hormonal Contraceptive Market by Gender
6.3.1 Market Overview
6.3.2 Male
6.3.3 Female
6.4 Global Hormonal Contraceptive Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.4.4 Clinics
6.4.5 Gynecology Centers
6.4.6 Ambulatory Surgical Centers (ASC)
6.5 Global Hormonal Contraceptive Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Hormonal Contraceptive Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Hormonal Contraceptive Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Hormonal Contraceptive Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Hormonal Contraceptive Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Hormonal Contraceptive Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 Allergan Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Pfizer Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bayer AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Afaxys, Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Merck and Co., Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Teva Pharmaceutical Industries Ltd.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Sun Pharmaceutical Industries Ltd.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Reckitt Benckiser Group plc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Boehringer Ingelheim International GmbH.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Agile Technologies
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Warner Chilcott
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Novartis AG
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Hormonal Contraceptive Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Allergan Inc.
  • Pfizer Inc.
  • Bayer AG
  • Afaxys, Inc.
  • Merck and Co. Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group plc.
  • Boehringer Ingelheim International Gmbh.
  • Agile Technologies
  • Warner Chilcott
  • Novartis Ag



Table Information